Moderna has announced that two smaller-sized doses of its COVID-19 vaccine produced a powerful immune response in children enrolled in a clinical trial and proved to be safe for people as young as 6 years old.

Washington, October 27 (RHC)-- Moderna has announced that two smaller-sized doses of its COVID-19 vaccine produced a powerful immune response in children enrolled in a clinical trial and proved to be safe for people as young as 6 years old.  

Moderna hasn’t yet publicly released its data, and the results are not yet peer reviewed.

An FDA advisory committee is meeting to review Pfizer’s application for emergency use of its COVID vaccine for U.S. children aged 5 to 11.  Final approval from the CDC could come as soon as next week. 

The American Academy of Pediatrics reports about a quarter of all COVID-19 cases over the last week were among children, with over 118,000 infections.